SOURCE: Equity Markets Inc.

June 29, 2011 09:00 ET

Research Report on Vertex Pharmaceuticals Inc. and PharmAthene, Inc. - Gaining in the Bio Pharmaceutical Sector

MACAU--(Marketwire - Jun 29, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting Vertex Pharmaceuticals Inc . (NASDAQ: VRTX) and PharmAthene, Inc. (NYSE Amex: PIP). Full content and research is available at www.EquityMarketsInc.com/research.php.

This sector demonstrates renewed investor interest as new and lucrative therapies come to market. The FDA approved the first new drug in 50 years to treat auto-immune disorder lupus in March 2011, and we expect approval of new treatments for Hepatitis C virus around mid-year. The 2010 health care reform act authorized the FDA, will establish a regulatory pathway for approving "biosimilar" drugs, which in turn will increase production and shorten FDA approval times. Longer term, it is expected that a wider acceptance of biomarker research and genetic-targeted clinical studies to help limit expense. It is viewed that therapeutics for cancer and infectious diseases and autoimmune and inflammatory treatments are primary growth areas.

Equity Markets has reviewed Vertex Pharmaceuticals Inc. which is in the business of discovering, developing and commercializing small molecule drugs for the treatment of diseases. The Company is engaged in phase-I clinical trials and/or nonclinical activities with respect to a range of additional drug candidates, including compounds intended for the treatment of hepatitis C virus (HCV) infection, cystic fibrosis (CF) and influenza. In November 2010, the Company submitted a new drug application (NDA), requesting approval to market telaprevir in the United States for the treatment of patients with chronic HCV infection. The full research report on Vertex Pharmaceuticals Inc . (NASDAQ: VRTX) is available here: www.EquityMarketsInc.com/researchfile4634.php.

Equity Markets is covering PharmAthene, Inc. as a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical weapons. It has five product candidates in various stages of development: SparVax, recombinant protective antigen (rPA) anthrax vaccine; Valortim, a human monoclonal antibody for the prevention and treatment of anthrax infection; Protexia, a recombinant enzyme (butyrylcholinesterase), which mimics a natural bioscavenger for the prevention or treatment of nerve agent poisoning by organophosphate compounds. The full research report on PharmAthene, Inc. (NYSE Amex: PIP) is available here: www.EquityMarketsInc.com/researchfile4891.php.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information